Europe
While the Danish drugmaker’s Tresiba (insulin degludec) didn’t fare as well as hoped in the head-to-head trial, Novo Nordisk was quick to point out that Tresiba showed an overall lower risk of hypoglycemia compared to Toujeo.
Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week’s appointments.
Working with a new class of cancer drugs called G12C KRAS inhibitors, researchers at the Francis Crick Institute and The Institute of Cancer Research (ICR), London, developed drug combinations to stay ahead of drug resistant tumors.
MorphoSys AG will present at the following conferences
Primary results showed significantly greater reduction in blood sugar levels over 26 weeks after switching to Soliqua® / Suliqua® 1 vs staying on daily or weekly GLP-1 receptor agonist
The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of cancer
Almac Group, the global contract pharmaceutical development and manufacturing organization, is pleased to announce its participation in the Global Clinical Supply BlockChain working group.
OECD estimates non adherence to pill regimes cause 200,000 premature deaths a year in EU and costs EUR 125 billion in the US $105 billion in US
Biotech and pharma companies from across the globe share updates on company business and pipelines.
Erleada is an androgen receptor inhibitor approved for non-metastatic castration-resistant prostate cancer.
PRESS RELEASES